
Aclarion Inc (ACON) Stock Forecast & Price Target
Aclarion Inc (ACON) Analyst Ratings
Bulls say
Aclarion is well positioned with a healthy cash runway and a strong balance sheet, having ended Q1 with $19.0 million in cash and no debt. The company's recent share repurchase program and ongoing clinical trial for its product Nociscan are positive signals for its positioning and valuation. Aclarion's investments in sales, R&D, and IR also demonstrate management's commitment to driving growth and success in the healthcare technology market, which has a large available market opportunity and promising demand for Nociscan.
Bears say
Aclarion is experiencing a positive trend in its commercial growth, with an increase in imaging centers, physician users, and expansion into different markets. However, there are potential risks to the company's future success, including financial, regulatory, and competition-related factors, which may impact investor sentiment for healthcare stocks.
This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.
Aclarion Inc (ACON) Analyst Forecast & Price Prediction
Start investing in Aclarion Inc (ACON)
Order type
Buy in
Order amount
Est. shares
0 shares